These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36707679)

  • 1. Virtual screening and molecular dynamics simulations provide insight into repurposing drugs against SARS-CoV-2 variants Spike protein/ACE2 interface.
    Pirolli D; Righino B; Camponeschi C; Ria F; Di Sante G; De Rosa MC
    Sci Rep; 2023 Jan; 13(1):1494. PubMed ID: 36707679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Computational repurposing approach for targeting the critical spike mutations in B.1.617.2 (delta), AY.1 (delta plus) and C.37 (lambda) SARS-CoV-2 variants using exhaustive structure-based virtual screening, molecular dynamic simulations and MM-PBSA methods.
    Ebrahimi M; Karami L; Alijanianzadeh M
    Comput Biol Med; 2022 Aug; 147():105709. PubMed ID: 35728285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.
    Shahbazi B; Mafakher L; Teimoori-Toolabi L
    J Mol Model; 2022 Mar; 28(4):82. PubMed ID: 35249180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of SARS-CoV-2 Cell Entry Inhibitors by Drug Repurposing Using
    Choudhary S; Malik YS; Tomar S
    Front Immunol; 2020; 11():1664. PubMed ID: 32754161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug repurposing against SARS-CoV-2 receptor binding domain using ensemble-based virtual screening and molecular dynamics simulations.
    Kumar V; Liu H; Wu C
    Comput Biol Med; 2021 Aug; 135():104634. PubMed ID: 34256255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxalic acid blocked the binding of spike protein from SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variants to human angiotensin-converting enzymes 2.
    Wang M; Yan H; Chen L; Wang Y; Li L; Zhang H; Miao L
    PLoS One; 2023; 18(5):e0285722. PubMed ID: 37200310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J).
    Kalamatianos KG
    Mol Divers; 2023 Jun; 27(3):1087-1099. PubMed ID: 35739375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico binding profile characterization of SARS-CoV-2 spike protein and its mutants bound to human ACE2 receptor.
    Zhang Y; He X; Zhai J; Ji B; Man VH; Wang J
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34013346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.
    Bharathi M; Sivamaruthi BS; Kesika P; Thangaleela S; Chaiyasut C
    Mar Drugs; 2022 Feb; 20(2):. PubMed ID: 35200677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
    Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
    IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathway enrichment analysis of virus-host interactome and prioritization of novel compounds targeting the spike glycoprotein receptor binding domain-human angiotensin-converting enzyme 2 interface to combat SARS-CoV-2.
    Gollapalli P; B S S; Rimac H; Patil P; Nalilu SK; Kandagalla S; Shetty P
    J Biomol Struct Dyn; 2022 Apr; 40(6):2701-2714. PubMed ID: 33146070
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Br B; Damle H; Ganju S; Damle L
    F1000Res; 2020; 9():663. PubMed ID: 32765844
    [No Abstract]   [Full Text] [Related]  

  • 18. Assessment of mutations on RBD in the Spike protein of SARS-CoV-2 Alpha, Delta and Omicron variants.
    da Costa CHS; de Freitas CAB; Alves CN; Lameira J
    Sci Rep; 2022 May; 12(1):8540. PubMed ID: 35595778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potential inhibitors of SARS-CoV-2 S protein-ACE2 interaction by
    Tristán-Flores FE; Casique-Aguirre D; Pliego-Arreaga R; Cervantes-Montelongo JA; García-Gutierrez P; Acosta-García G; Silva-Martínez GA
    F1000Res; 2021; 10():. PubMed ID: 34900223
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region.
    Pourmand S; Zareei S; Shahlaei M; Moradi S
    Comput Biol Med; 2022 Jul; 146():105625. PubMed ID: 35688710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.